# EDGAR Filing Document

**Accession Number:** 0001614744
**File Stem:** 0001213900-25-082613
**Filing Date:** 2025-8
**Character Count:** 2536
**Document Hash:** df7d5703c5500a4a3461f32680733473
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-082613.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001213900-25-082613

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PURPLE BIOTECH LTD.
- **CENTRAL INDEX KEY:** 0001614744
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4 OPPENHEIMER STREET
- **STREET 2:** SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670104
- **BUSINESS PHONE:** 97239333121

**MAIL ADDRESS:**
- **STREET 1:** 4 OPPENHEIMER STREET
- **STREET 2:** SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kitov Pharma Ltd.
- **DATE OF NAME CHANGE:** 20180125

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kitov Pharmaceuticals Holdings Ltd.
- **DATE OF NAME CHANGE:** 20140724

**Purple Biotech Ltd.**

4 Oppenheimer Street, Science Park

Rehovot 7670104, Israel

August 29, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission<br> Division of Corporation Finance

Office of Life Sciences

100 F Street N.E.<br> Washington, D.C. 20549

Attention: Lauren Hamill

Re: Purple Biotech Ltd.<br> Registration Statement on Form F-1

Filed August 29, 2025

File No. 333-289927 (the "***Registration Statement***")

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Purple Biotech Ltd. (the "***Company***") hereby respectfully requests that the effective date of the Company's Registration Statement be accelerated by the Securities and Exchange Commission to 9:00 a.m., Eastern Time on September 3, 2025, or as soon thereafter as practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company's counsel, Haynes and Boone, LLP, by calling Jayun Koo at (212) 835-4823, and that such effectiveness also be confirmed in writing.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| Purple Biotech Ltd. | Purple Biotech Ltd. |
| By: | */s/ Gil Efron* |
|  | Gil Efron<br> Chief Executive Officer |

---

cc: Rick A. Werner, Esq., Haynes and Boone, LLP <br> Jayun Koo, Esq., Haynes and Boone, LLP